多粘菌素α治疗囊性纤维化患者慢性鼻窦炎的系统综述
该系统综述遵循PRISMA声明,检索1990至2016年文献,最终纳入6项研究共104例患者。结果显示鼻内局部应用多粘菌素α在改善鼻窦症状方面优于生理盐水,但对肺功能及影像和内镜表现的影响不一,需更大规模研究验证。
要点
- 鼻内局部多粘菌素α可改善囊性纤维化患者的鼻窦症状。
- 三项安慰剂对照研究显示局部多粘菌素α改善鼻窦症状优于单用生理盐水。
- 对肺功能、影像学及内镜表现的影响各研究结果不一致。
核心结论
- 鼻内局部多粘菌素α在改善囊性纤维化患者鼻窦症状方面似乎优于单用生理盐水,但对其他结局的影响尚不明确。
研究设计与样本
- 遵循PRISMA声明的系统综述,检索Ovid Medline、EMBASE、PubMed和Cochrane Library,最终纳入6项研究共104例患者。
主要发现
- 所有研究均显示鼻内局部多粘菌素α可改善鼻窦症状。
- 三项安慰剂对照研究显示局部多粘菌素α改善鼻窦症状显著优于单用生理盐水。
- 对肺功能、影像学及内镜表现的影响各研究报道不一。
关键数值与推荐
- 三项安慰剂对照研究显示局部多粘菌素α改善鼻窦症状显著优于单用生理盐水。
临床怎么用
- 对于囊性纤维化合并慢性鼻窦炎的患者,可考虑鼻内局部应用多粘菌素α以改善鼻窦症状。
局限性
- 纳入研究数量少(6项)且样本量小(104例),各研究结局报道不一致,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A major component of sputum in cystic fibrosis (CF) patients is polymerized DNA, a byproduct of degraded neutrophils. Dornase alfa (dornase) selectively cleaves extracellular DNA and reduces the viscosity of sputum. It improves mucociliary clearance and pulmonary function. The benefit of dornase on CF-associated sinusitis is less clear. Therefore, the objective of this study was to systematically review the use of dornase on chronic rhinosinusitis (CRS) in CF patients. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed for this systematic review. Ovid Medline, EMBASE, PubMed, and the Cochrane Library were searched. The search terms "dornase alfa," "deoxyribonucleases," "rhinosinusitis," and "cystic fibrosis" were used to find articles published between 1990 and 2016. The articles were reviewed for study design, level of evidence, and clinical outcomes. RESULTS: Sixty-two articles were identified; 6 met the inclusion criteria (104 patients). Improvement measured by sinonasal symptoms, endoscopic and radiographic findings, and pulmonary function was variably reported between the studies. Sinonasal symptoms were shown to improve in all studies with use of intranasal topical dornase. Three placebo-controlled studies showed that topical dornase significantly improved sinonasal symptoms more than saline alone. The impact on pulmonary function and radiographic and endoscopy findings was variable. CONCLUSION: Topical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients.
引用
- Shah GB, De Keyzer L, Russell JA, et al. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review. Int Forum Allergy Rhinol. 2018. PMID: 29323796. doi:10.1002/alr.22082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。